Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 12:13:100195.
doi: 10.1016/j.lrr.2020.100195. eCollection 2020.

Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia

Laura Kearney  1 , Mireille Crampe  1 , Eibhlin Conneally  2 , Janusz Krawczyk  3 , Senthil Kumar  4 , Philip T Murphy  5 , Vitaliy Mykytiv  6 , Mary-Frances Ryan  7 , Stephen E Langabeer  1
Affiliations

Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia

Laura Kearney et al. Leuk Res Rep. .
No abstract available

Keywords: BCR-ABL1; Chronic myeloid leukemia; Molecular response; e19a2.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest.

References

    1. Baccarani M., Castagnetti F., Gugliotta G., Rosti G., Soverini S., Pfirrmann M., International BCR-ABL1 Study Group The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. Int. Overv. Leuk. 2019;33:1173–1183. - PubMed
    1. Gong Z., Medeiros L.J., Cortes J.E., Zheng L., Khoury J.D., Wang W., Tang G., Loghavi S., Luthra R., Yang W., Kantarjian H.M., Hu S. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017;7:e583. - PMC - PubMed
    1. Langabeer S.E., McCarron S.L., Carroll P., Kelly J., O'Dwyer M., Conneally E. Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. Leuk, Res. 2011;356:e169–e170. - PubMed
    1. Qin Y.Z., Jiang Q., Jiang H., Lai Y.Y., Shi H.X., Chen W.M. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: data from a single centre. Br. J. Haematol. 2018;182:693–700. - PubMed
    1. Hanfstein B., Lauseker M., Hehlmann R., Saussele S., Erben P., Dietz C. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441–1447. - PMC - PubMed

LinkOut - more resources